<div id="isi-menopur" class="popup mfp-hide terms-and-conditions modal-isi">
	<div class="popup-body container-fluid">
		<button title="Close (Esc)" type="button" class="mfp-close">×</button>
		<h3>MENOPUR® (menotropins for injection)</h3>
			<h4>INDICATION FOR USE</h4>
			<ul>
				<li>MENOPUR® (menotropins for injection), administered subcutaneously, is indicated for the development
					of multiple follicles and pregnancy in the ovulatory patients participating in an Assisted
					Reproductive Technology (ART) program.</li>
			</ul>
			<h4>IMPORTANT SAFETY INFORMATION</h4>
			<ul>
				<li>MENOPUR is contraindicated in women who have: a high FSH level indicating primary ovarian failure,
					presence of uncontrolled non-gonadal endocrinopathies, tumors of the pituitary gland or
					hypothalamus, sex hormone dependent tumors of the reproductive tract and accessory organs, abnormal
					uterine bleeding of undetermined origin, ovarian cysts or enlargement of undetermined origin, not
					due to polycystic ovary syndrome, or prior hypersensitivity to menotropins or MENOPUR. MENOPUR is
					not indicated in women who are pregnant and may cause fetal harm when administered to a pregnant
					woman</li>
				<li>MENOPUR should only be used by physicians who are thoroughly familiar with infertility problems.
					MENOPUR is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome
					(OHSS), with or without pulmonary or vascular complications, in women undergoing therapy for
					infertility. Ovarian torsion has been reported after gonadotropin treatment. Serious pulmonary
					conditions and thromboembolic events have been reported with MENOPUR. There have been infrequent
					reports of ovarian neoplasms with MENOPUR. Multiple pregnancies, spontaneous abortion, congenital
					malformations and ectopic pregnancies have occurred following treatment with MENOPUR.</li>
				<li>The most common adverse reactions (≥2%) in ART include: abdominal cramps; abdomen enlarged;
					abdominal pain; headache; injection site pain and reaction; injection site inflammation; OHSS.</li>
			</ul>
	</div>
</div>